37S Stock Chart & Stats
€0.12
<€0.01(1.53%)
At close: 4:00 PM EDT
€0.12
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.11 - €0.26
Previous CloseN/A
Volume0.00
Average Volume (3M)559.00
Market Cap
€4.19M
Enterprise Value€3.44
Total Cash (Recent Filing)€3.50M
Total Debt (Recent Filing)€1.53M
Price to Earnings (P/E)―
Beta0.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,544,390
10 Day Avg. Volume0
30 Day Avg. Volume559
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.23
Price to Sales (P/S)0.43
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin RecoverySustained revenue growth and a rebound in gross margin to ~26% indicate improving product adoption and pricing/mix dynamics. These trends support a durable pathway to operating leverage as procedure volumes and commercialization efforts continue, aiding profitability over the medium term.
Conservative Leverage / Balance-sheet ResilienceVery low debt relative to equity provides financial flexibility and resilience while the company invests in growth and works toward profitability. This conservative capital structure reduces refinancing risk and preserves optionality for R&D or market expansion over the next several quarters.
Operating Cash Flow Turned PositiveA return to positive operating cash flow signals better working-capital management and underlying cash generation from core operations. Even if free cash flow remains constrained, positive OCF is a durable improvement that lowers dependence on external funding when sustained.
Bears Say
Ongoing Net LossesPersistent negative net margins mean the business is not yet converting revenue growth into bottom-line profits. Continued losses risk depleting reserves or requiring external capital, and they limit the company's ability to deliver positive shareholder returns until profitability is achieved and sustained.
Free Cash Flow WeaknessAn inability to generate positive free cash flow after investments constrains reinvestment and heightens reliance on financing. Even with OCF improvement, persistent zero/negative FCF limits strategic flexibility and raises risk if revenue or margin improvements slow.
Small Commercial ScaleA small employee base implies limited internal sales, clinical support and geographic reach versus larger competitors. Scaling to capture broader market share will likely require sustained investment in sales and distribution, pressure margins, and slow structural market penetration.
Spineway SA News
37S FAQ
What was Spineway SA’s price range in the past 12 months?
Spineway SA lowest stock price was €0.11 and its highest was €0.26 in the past 12 months.
What is Spineway SA’s market cap?
Spineway SA’s market cap is €4.19M.
When is Spineway SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Spineway SA’s earnings last quarter?
Currently, no data Available
Is Spineway SA overvalued?
According to Wall Street analysts Spineway SA’s price is currently Overvalued.
Does Spineway SA pay dividends?
Spineway SA does not currently pay dividends.
What is Spineway SA’s EPS estimate?
Spineway SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spineway SA have?
Spineway SA has 35,544,390 shares outstanding.
What happened to Spineway SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Spineway SA?
Currently, no hedge funds are holding shares in DE:37S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spineway SA
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.